IRIS
PASSAMONTI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.580
AS - Asia 2.557
EU - Europa 2.347
SA - Sud America 257
AF - Africa 45
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 6
Totale 8.800
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.505
CN - Cina 1.524
SG - Singapore 523
IE - Irlanda 498
UA - Ucraina 384
HK - Hong Kong 311
FI - Finlandia 295
DE - Germania 272
RU - Federazione Russa 234
BR - Brasile 201
IT - Italia 165
SE - Svezia 152
GB - Regno Unito 120
FR - Francia 115
VN - Vietnam 65
CA - Canada 40
IN - India 39
PL - Polonia 26
AR - Argentina 25
MX - Messico 25
NL - Olanda 21
JP - Giappone 16
BE - Belgio 15
ZA - Sudafrica 15
BD - Bangladesh 14
ES - Italia 10
SA - Arabia Saudita 10
EC - Ecuador 8
LT - Lituania 8
AT - Austria 7
CO - Colombia 7
MU - Mauritius 7
PY - Paraguay 7
TR - Turchia 7
AU - Australia 6
EU - Europa 6
IQ - Iraq 5
JO - Giordania 5
VE - Venezuela 5
EG - Egitto 4
MA - Marocco 4
NP - Nepal 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
CH - Svizzera 3
DZ - Algeria 3
GR - Grecia 3
IL - Israele 3
IR - Iran 3
LA - Repubblica Popolare Democratica del Laos 3
MY - Malesia 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CL - Cile 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
GA - Gabon 2
ID - Indonesia 2
JM - Giamaica 2
KE - Kenya 2
NG - Nigeria 2
PA - Panama 2
PE - Perù 2
PK - Pakistan 2
SN - Senegal 2
SY - Repubblica araba siriana 2
UZ - Uzbekistan 2
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GD - Grenada 1
GE - Georgia 1
HU - Ungheria 1
KG - Kirghizistan 1
KR - Corea 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LV - Lettonia 1
MT - Malta 1
NO - Norvegia 1
PH - Filippine 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UG - Uganda 1
Totale 8.800
Salva come PNG Salva come JPEG
Città #
Chandler 548
Dublin 498
Jacksonville 470
Nanjing 352
Hong Kong 311
Dallas 291
Singapore 234
Ashburn 230
Beijing 230
Boardman 189
Nanchang 135
Hebei 116
Princeton 112
Shenyang 109
Lawrence 108
Los Angeles 104
Medford 102
Wilmington 102
Changsha 98
New York 94
Ann Arbor 84
Jiaxing 69
Lauterbourg 69
Helsinki 63
Tianjin 61
Hangzhou 54
Munich 42
Shanghai 38
Woodbridge 38
Milan 36
Buffalo 35
Moscow 34
Redondo Beach 34
Ho Chi Minh City 29
Warsaw 22
Turku 20
Council Bluffs 19
Santa Clara 19
Norwalk 16
San Francisco 16
Tokyo 16
Brussels 15
Des Moines 14
Toronto 14
Verona 14
Fairfield 13
Nuremberg 13
Pavia 13
Falkenstein 12
Seattle 12
São Paulo 12
The Dalles 12
Auburn Hills 11
Hanoi 11
Johannesburg 11
Montreal 11
Stockholm 10
Boston 9
Brooklyn 9
Florence 9
Jinan 9
Kunming 9
Rome 9
Atlanta 8
Denver 8
Ningbo 8
Orem 8
Poplar 8
Pune 8
Chennai 7
Genoa 7
Guangzhou 7
Phoenix 7
Rio de Janeiro 7
Taizhou 7
Zhengzhou 7
Chicago 6
Falls Church 6
Guayaquil 6
Lanzhou 6
Mexico City 6
Riyadh 6
San Jose 6
Tappahannock 6
Xi'an 6
Amman 5
Columbus 5
Frankfurt am Main 5
London 5
Manchester 5
New Delhi 5
Wuhan 5
Belo Horizonte 4
Charleston 4
Charlotte 4
Dearborn 4
Houston 4
Ribeirão Preto 4
Secaucus 4
Shenzhen 4
Totale 5.717
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 162
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 162
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. 143
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 128
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. 126
Blast phase of essential thrombocythemia: A single center study. 120
Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. 120
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndrome 117
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 112
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 111
A gain-of-function mutation of JAK2 in myeloproliferative disorders 108
EFFICACY OF PIPOBROMAN IN THE TREATMENT OF POLYCYTHEMIA VERA: LONG TERM RESULTS IN 163 PATIENTS 107
Clinical Predictors of Outcome in MPN. 107
A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients 107
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. 104
Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis 103
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 102
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process 102
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons 102
Looking for CALR mutations in familial myeloproliferative neoplasms 102
JAK2 (V617F) mutation in healthy individuals 101
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 101
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA 98
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinibversusbest available therapy 97
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug 96
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) 96
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 94
Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders 93
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. 91
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 90
EFFICACY OF A IDARUBICIN, ETOPOSIDE AND INTERMEDIATE-DOSE CYTARABINE ARABINOSIDE AS SALVAGE THERAPY IN RELAPSING OR RESISTANT UNFAVORABLE LYMPHOMA 89
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report 89
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 89
Leukemia risk models in primary myelofibrosis: an International Working Group study. 88
Balancing efficacy and safety of JAK inhibitors in myelofibrosis 88
Clinical relevance of JAK2 (V617F) mutant allele burden 88
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 87
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 87
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 85
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 84
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 84
Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-positive Diffuse Large B-cell Lymphomas 81
TREATMENT OF EARLY STAGE HODGKIN’S DISEASE WITH FOUR CYCLES OF ABVD FOLLOWED BY ADJUVANT RADIOTHERAPY: ANALYSIS OF EFFICACY AND LONG TERM TOXICITY 80
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 79
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 79
Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. 79
Exaggerated insect bite-like reaction in patients affected by oncohaematological diseases 78
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 78
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. 78
PDGFRB disease: right diagnosis to prolong survival 78
Looking for familial nodular lymphocyte-predominant Hodgkin lymphoma 78
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 78
Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders 77
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 76
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera 76
Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. 75
Pomalidomide is active in the treatment of anemia associated with myelofibrosis 75
Leucemia mieloide cronica e sindromi mieloproliferative croniche 74
Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies 74
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history 74
New generation small-molecule inhibitors in myeloproliferative neoplasms 74
Myeloproliferative Neoplasms 72
Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients 72
Pityriasis roseaelike eruption during treatment with imatinib mesylate: Description of 3 cases 71
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. 71
How I treat polycythemia vera. 71
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs 71
EX VIVO MANIPULATION OF HEMATOPOIETIC STEM CELLS FOR TRANSPLANTATION: THE POTENTIAL ROLE OF AMIFOSTINE.SEMINARS IN ONCOLOGY. 70
Survival in young patients with intermediate-/high-risk myelofibrosis: Estimates derived from databases for non transplant patients 70
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. 70
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 70
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas 70
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making 69
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment 69
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 69
Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis 69
European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. 68
LE NEOPLASIE MIELOPROLIFERATIVE PHILADELPHIA NEGATIVE 68
Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. 67
Mutational status of myeloproliferative neoplasms. 66
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. 65
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project 65
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN. 64
How to manage polycythemia vera 64
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. 64
Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper 64
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms 64
What are RBC-transfusion-dependence and -independence? 62
Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy 62
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients 62
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. 62
RBC-transfusion guidelines update 61
Ruxolitinib and survival improvement in patients with myelofibrosis 61
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. 61
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia 61
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment 60
JAK inhibitor in CALR-mutant myelofibrosis. 59
Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi 55
Leukemic transformation of polycythemia vera: a single center study of 23 patients 54
It is time to change thrombosis risk assessment for PV and ET? 54
Totale 8.348
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.016
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.016
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021434 0 0 0 0 0 90 5 100 28 96 94 21
2021/2022493 11 6 11 6 19 11 6 29 21 17 82 274
2022/20231.573 168 96 18 149 150 180 2 102 632 11 32 33
2023/2024537 79 92 16 48 34 157 3 33 4 11 15 45
2024/20251.427 29 127 36 39 40 66 43 117 335 34 229 332
2025/20261.926 280 335 413 347 355 196 0 0 0 0 0 0
Totale 8.913